207 related articles for article (PubMed ID: 22434677)
1. Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.
Butelman ER; Caspers M; Lovell KM; Kreek MJ; Prisinzano TE
J Pharmacol Exp Ther; 2012 Jun; 341(3):802-8. PubMed ID: 22434677
[TBL] [Abstract][Full Text] [Related]
2. Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid.
Butelman ER; Prisinzano TE; Deng H; Rus S; Kreek MJ
J Pharmacol Exp Ther; 2009 Feb; 328(2):588-97. PubMed ID: 19001155
[TBL] [Abstract][Full Text] [Related]
3. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Butelman ER; Rus S; Prisinzano TE; Kreek MJ
Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
[TBL] [Abstract][Full Text] [Related]
4. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
[TBL] [Abstract][Full Text] [Related]
5. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
Butelman ER; Harris TJ; Kreek MJ
Psychopharmacology (Berl); 2004 Mar; 172(2):220-4. PubMed ID: 14586540
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.
Baker LE; Panos JJ; Killinger BA; Peet MM; Bell LM; Haliw LA; Walker SL
Psychopharmacology (Berl); 2009 Apr; 203(2):203-11. PubMed ID: 19153716
[TBL] [Abstract][Full Text] [Related]
7. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
8. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
Cruz A; Domingos S; Gallardo E; Martinho A
Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
[TBL] [Abstract][Full Text] [Related]
9. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
[TBL] [Abstract][Full Text] [Related]
10. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.
Zhang Y; Butelman ER; Schlussman SD; Ho A; Kreek MJ
Psychopharmacology (Berl); 2005 May; 179(3):551-8. PubMed ID: 15682306
[TBL] [Abstract][Full Text] [Related]
11. The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.
Willmore-Fordham CB; Krall DM; McCurdy CR; Kinder DH
Neuropharmacology; 2007 Sep; 53(4):481-6. PubMed ID: 17681558
[TBL] [Abstract][Full Text] [Related]
12. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
MacLean KA; Johnson MW; Reissig CJ; Prisinzano TE; Griffiths RR
Psychopharmacology (Berl); 2013 Mar; 226(2):381-92. PubMed ID: 23135605
[TBL] [Abstract][Full Text] [Related]
13. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.
Johnson MW; MacLean KA; Reissig CJ; Prisinzano TE; Griffiths RR
Drug Alcohol Depend; 2011 May; 115(1-2):150-5. PubMed ID: 21131142
[TBL] [Abstract][Full Text] [Related]
14. Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.
Vasiljevik T; Groer CE; Lehner K; Navarro H; Prisinzano TE
J Nat Prod; 2014 Aug; 77(8):1817-24. PubMed ID: 25075762
[TBL] [Abstract][Full Text] [Related]
15. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.
Schmidt MD; Schmidt MS; Butelman ER; Harding WW; Tidgewell K; Murry DJ; Kreek MJ; Prisinzano TE
Synapse; 2005 Dec; 58(3):208-10. PubMed ID: 16138318
[TBL] [Abstract][Full Text] [Related]
17. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL
Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680
[TBL] [Abstract][Full Text] [Related]
18. Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.
Polepally PR; White K; Vardy E; Roth BL; Ferreira D; Zjawiony JK
Bioorg Med Chem Lett; 2013 May; 23(10):2860-2. PubMed ID: 23587424
[TBL] [Abstract][Full Text] [Related]
19. Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole.
Beerepoot P; Lam V; Luu A; Tsoi B; Siebert D; Szechtman H
Neurosci Lett; 2008 Dec; 446(2-3):101-4. PubMed ID: 18824069
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.
Ansonoff MA; Zhang J; Czyzyk T; Rothman RB; Stewart J; Xu H; Zjwiony J; Siebert DJ; Yang F; Roth BL; Pintar JE
J Pharmacol Exp Ther; 2006 Aug; 318(2):641-8. PubMed ID: 16672569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]